Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 5.6% Higher - Time to Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was up 5.6% on Thursday . The stock traded as high as $5.25 and last traded at $5.11. Approximately 34,999,933 shares were traded during mid-day trading, an increase of 129% from the average daily volume of 15,280,945 shares. The stock had previously closed at $4.84.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on RXRX shares. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Morgan Stanley decreased their target price on Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating for the company in a research report on Monday, June 16th. Finally, Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $7.00.

Recursion Pharmaceuticals Price Performance

The stock has a market cap of $2.04 billion, a PE ratio of -2.84 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The business has a fifty day moving average of $4.92 and a 200 day moving average of $6.25.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The business had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.39) EPS. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Man Group plc acquired a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $479,000. Rockefeller Capital Management L.P. raised its stake in Recursion Pharmaceuticals by 323.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock valued at $1,906,000 after buying an additional 215,283 shares in the last quarter. Invesco Ltd. raised its stake in Recursion Pharmaceuticals by 54.6% during the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company's stock valued at $1,207,000 after buying an additional 63,068 shares in the last quarter. Norges Bank acquired a new stake in Recursion Pharmaceuticals during the fourth quarter valued at approximately $23,429,000. Finally, California State Teachers Retirement System raised its stake in Recursion Pharmaceuticals by 30.7% during the fourth quarter. California State Teachers Retirement System now owns 231,535 shares of the company's stock valued at $1,565,000 after buying an additional 54,449 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.